カテゴリ： GlobalData, アメリカ, 企業調査

Eli Lilly and Co (LLY)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：Eli Lilly and Co (LLY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8010865
◆発行会社（調査会社）：GlobalData
◆発行日：2017年12月20日
◆ページ数：347
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Eli Lilly and Company (Lilly) is a healthcare company that discovers, develops and markets human and animal healthcare products. The company offers medicines for cardiovascular conditions, diabetes, cancer, neurological problems, critical care, men’s health and musculoskeletal problems. It also provides pet medicine, food-safety products and companion animal health products, besides services to the food animal industry. Lilly also has mid-to-late stage pipeline portfolio for conditions such as diabetes, cancer, neurological problems and autoimmune disorders. The company distributes human pharmaceutical and animal health products through independent wholesale distributors. It also promotes its products through sales representatives and marketing agreements with other pharmaceutical companies. The company offers its products in the US, Europe, Japan and Other foreign countries. Lilly is headquartered in Indianapolis, Indiana, the US.

Eli Lilly and Co (LLY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 9
List of Figures 12
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Eli Lilly and Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 16
Eli Lilly and Co, Medical Devices Deals, 2011 to YTD 2017 18
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deal Details 33
Asset Purchase 33
Eli Lilly Acquires Rights to Intranasal Glucagon from Locemia Solutions 33
Eli Lilly Acquires CGRP Antibody From Arteaus Therapeutics 34
Venture Financing 35
Kymera Therapeutics Raises USD30 Million in Series A Venture Financing 35
Gritstone Oncology Raises USD92.7 Million in Series B Financing 36
Hangzhou Just Biotherapeutics Raises USD57 Million in Series B Financing 38
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 40
E-scape Bio Raises Additional USD8 Million in Series A Financing 42
Abbisko Therapeutics Raises USD28 Million in Series A Financing 43
Cavion Raises USD26 Million in Series A Financing 44
ApoGen Biotech Raises USD7 Million in Series A Financing 45
ReadCoor Raises USD23 Million in Series A Financing 46
Fortis Therapeutics Raises USD18 Million in Series A Financing 47
Singlera Genomics Raises USD20 Million in Series A Financing 48
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 49
IMPACT Therapeutics Raises USD10 Million in Series B Financing 51
Lodo Therapeutics Raises USD17 Million in Series A Financing 52
Zymeworks Raises USD61.5 Million in Series A Financing 54
Petra Pharma Raises USD48 Million in Series A Financing 56
NextCure Raises USD67 Million in Series A Financing 58
Symic Biomedical Raises USD25 Million in Series A-2 Financing 60
ACEA Biosciences Raises USD30 Million in Venture Financing 61
Tianjin CanSino Biotech Raises USD30 Million in Venture Financing Round 62
MabSpace Biosciences Raises USD15 Million in Series A Financing Round 63
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 64
E-scape Bio Raises USD55 Million in Series A Financing 65
Kawin Technology Raises Funds in Venture Financing 66
Protagonist Therapeutics Raises USD40 Million in Series C Financing 67
Innocrin Pharma Raises USD28 Million in Series D Financing 69
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 70
Nimbus Therapeutics Raises USD43 Million in Series B Financing 71
Lysosomal Therapeutics Raises USD20 Million in Series A Financing 72
Surface Oncology Raises USD35 Million in Series A Financing 73
Symic Biomedical Raises USD15 Million in Series A Financing 75
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 76
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 77
Innocrin Pharma Raises Funds through Venture Financing 79
Viamet Pharma Raises USD60 Million in Series D Venture Financing 80
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 81
IMPACT Therapeutics Raises Funds through Series A Financing 82
Numerate Raises USD8 Million in Financing Round 83
Crown Bioscience Raises USD27 Million in Series D Financing 84
Coherus BioSciences Raises USD55 Million in Series C Venture Financing 85
Lysosomal Therapeutics Raises US$4.8 Million In Seed Financing 87
Audion Therapeutics Raises Funds Through Series A Financing Round 89
Sutro Biopharma Raises US$26 Million In Series D Financing 90
Aileron Therapeutics Raises US$30 Million In Series E Financing 92
Tianjin CanSino Biotech Raises US$10 Million In Venture Financing 94
Aileron Raises US$12 Million In Extended Series D Financing 95
Innovent Biologics Raises US$25 Million In Series B Financing 97
Chinese Peptide Raises Funds Through Series A Financing 98
Sutro Biopharma Raises US$16.5 Million In Second Tranche Of Series C Financing 99
HemaQuest Pharma Raises US$13 Million In Extended Series B Financing 100
Cerulean Pharma Secures US$15 Million In Series D Financing 101
Nimbus Discovery Secures US$24 Million In Series A Financing 103
Viamet Pharma Secures Additional US$15 Million In Series B Financing 104
Partnerships 105
ImClone Systems Enters Licensing Agreement with Zymeworks 105
Eli Lilly and CureVac Enter into Partnership 106
Topas Therapeutics Enters into Research Agreement with Eli Lilly 107
Eli Lilly and Purdue University Enter into Research Agreement 108
Eli Lilly and KeyBioscience to Enter into Agreement 109
3SBio Enters into Distribution Agreement with Eli Lilly 110
Eli Lilly Enters into Research Agreement with William Sansum Diabetes Center 111
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 112
Athenex Enters into Partnership with Eli Lilly and Company 113
Eli Lilly Enters into Agreement with Boehringer Ingelheim 114
Regen BioPharma to Enter into Agreement with Eli Lilly 115
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 116
Eli Lilly Enters into Agreement with Roche Diagnostics International 117
Eli Lilly Expands its Agreement with Merck 118
WuXi PharmaTech Enters into Agreement with Eli Lilly 119
Yabao Pharma Enters into Co-Development Agreement with Eli Lilly 120
Eli Lilly Enters into Research Agreement with ImaginAb 121
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 122
Biothera Enters into Research Agreement with Eli Lilly 123
Eli Lilly Enters into Co-Development Agreement with Sarah Cannon Research Institute 124
Eli Lilly Enters into Research Agreement with Dana-Farber Cancer Institute 125
AstraZeneca Expands Research Agreement with Eli Lilly 126
Eli Lilly to Enter into Research Agreement with Sanford Burnham 127
Eli Lilly Enters into Research Agreement with BioNTech 128
Eli Lilly Expands Agreement with Innovent Biologics 129
Merck Expands Agreement with Eli Lilly 130
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 131
Eli Lilly Enters into Agreement with University of Surrey for Diabetes Research 132
Eli Lilly Enters into Research Agreement with Anthem and HealthCore 133
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim 134
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 136
Eli Lilly Enters into Co-Discover and Development Agreement with Immunocore 137
Yabao Pharma Enters into Co-Development Agreement with Eli Lilly for LY2608204 138
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 139
Prasco Labs Enters Into Distribution Agreement With Eli Lilly For Evista 140
Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 141
Project A.L.S. Enters Into Research Agreement With Eli Lilly 142
Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 143
Eli Lilly Enters Into Co-Development Agreement With University of Edinburgh 144
Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 145
Eli Lilly Enters Into Co-Development Agreement With Novast Labs 146
Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 147
Arecor Enters Into Co-Development Agreement With Eli Lilly For Protein Therapeutics 148
Starpharma Holdings Expands Research Agreement With Eli Lilly 149
Prasco Labs Enters Into Co-Marketing Agreement With Eli Lilly For ZYPREXA And ZYPREXA ZYDIS 150
Eli Lilly Enters Into Co-Promotion Agreement With Boehringer Ingelheim For Humalog And Linagliptin 151
Eli Lilly and Company (India) Expands its Agreement With Lupin 152
Synthes Enters Into Co-Development Agreement With Eli Lilly 153
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 154
Eli Lilly Enters Into Joint Venture Agreement With Care Capital And NovaQuest To Form BioCritica 156
Eli Lilly Enters Into Collaboration With Medtronic 157
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 158
Receptos Enters Into Collaboration With Eli Lilly 160
Licensing Agreements 161
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 161
Eli Lilly to Enter into Licensing Agreement with Nektar Therapeutics 162
Eli Lilly Enters into Licensing Agreement with Adimab 164
Lupin Enters into Licensing Agreement with Eli Lilly and Company 165
Intelgenx Enters into Licensing Agreement with Eli Lilly 166
Cerecor Enters into Licensing Agreement with Eli Lilly 167
Blackthorn Therapeutics Enters into Licensing Agreement with Eli Lilly 168
Eli Lilly Enters into Licensing Agreement with PeptiDream 169
Ignyta Amends Licensing Agreement with Eli Lilly 170
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 172
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 173
Cerecor Enters into Licensing Agreement with Eli Lilly 174
Amunix Exercises Option for Licensing Agreement with Eli Lilly 176
Eli Lilly Enters into Licensing Agreement with Zymeworks 177
Anthera Pharma Enters into Licensing Agreement with Eli Lilly for Sollpura 178
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 179
PeptiDream Enters Into Licensing Agreement With Eli Lilly 180
Hutchison MediTech Enters Into Licensing Agreement With Eli Lilly 181
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 183
Deciphera Pharma Extends Its Licensing Agreement With Eli Lilly and Company 184
Dekkun Enters into Licensing Agreement with Eli Lilly and Company 185
IntelGenx Enters into Licensing Agreement with Eli Lilly and Company 186
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 187
Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 188
Denovo Biopharma Enters into Licensing Agreement with Eli Lilly for Pomaglumetad Methionil 189
Audion Therapeutics Enters Into Licensing Agreement With Eli Lilly and Company 190
ImmunoGen Extends Licensing Agreement With Eli Lilly For Targeted Antibody Payload Technology 191
Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 192
Transition Therapeutics and Eli Lilly Amend Licensing Agreement 193
Strides Arcolab Enters Into Licensing Agreement With Eli Lilly For Generic Cancer Medicines 195
R-Pharm Enters into Licensing Agreement with Eli Lilly 196
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 197
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 199
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 200
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 201
Adocia Enters Into Licensing Agreement With Eli Lilly For BioChaperone 202
arGEN-X Enters Into Licensing Agreement With Eli Lilly 203
Equity Offering 204
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 204
Tmunity Therapeutics Raises USD10 Million in Equity Financing 206
Ignyta Raises USD30 Million in Private Placement of Shares 207
Immunocore Raises USD320 Million in Financing Round 208
Debt Offering 209
Eli Lilly Raises USD201 Million in Public Offering of Notes Due 2018 209
Eli Lilly Raises USD603.7 Million in Public Offering of 0.15% Notes Due 2024 210
Eli Lilly Raises USD402.5 Million in Public Offering of 0.45% Notes Due 2028 211
Eli Lilly Prices Public Offering of 2.1% Bonds Due 2030 for USD823.6 Million 212
Eli Lilly Prices Public Offering of 1.6% Bonds Due 2026 for USD823.6 Million 213
Eli Lilly Prices Public Offering of 1% Bonds Due 2022 for USD659 Million 214
Eli Lilly Raises USD800 Million in Public Offering of 2.75% Notes Due 2025 215
Eli Lilly Raises USD800 Million in Public Offering of 3.7% Notes Due 2045 216
Eli Lilly Raises USD600 Million in Public Offering of 1.25% Notes Due 2018 217
Eli Lilly Raises USD400 Million in Public Offering of 4.65% Notes Due 2044 218
Eli Lilly Raises USD600 Million in Public Offering of 1.95% Notes Due 2019 219
Asset Transactions 220
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 220
Eli Lilly to Sell Bio-manufacturing Plant in Vacaville, California 221
Virbac Acquires Sentinel Flavor Tabs and Sentinel Spectrum from Eli Lilly for USD410 Million 222
Denovo Biopharma Acquires Global Rights to Enzastaurin from Eli Lilly 223
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 224
Trimer Biotech Acquires AME-527 from Eli Lilly 225
MENTRIK Biotech Acquires Rights Of AME-133v From Eli Lilly 226
Acquisition 227
Eli Lilly Acquires CoLucid Pharma for USD960 Million in Tender Offer 227
Eli Lilly and Company Acquires Glycostasis 229
AstraZeneca May Acquire Ariad Pharma 230
Eli Lilly and Co – Key Competitors 232
Eli Lilly and Co – Key Employees 233
Eli Lilly and Co – Locations And Subsidiaries 235
Head Office 235
Other Locations & Subsidiaries 235
Joint Venture 242
Recent Developments 244
Strategy And Business Planning 244
Sep 07, 2017: Lilly Takes Steps To Streamline Business, Invest In New Medicines And Drive Growth 244
Financial Announcements 245
Dec 13, 2017: Lilly Announces 2018 Financial Guidance and Enhances Outlook Through 2020 245
Oct 24, 2017: Lilly Reports Third-Quarter Results 2017 246
Jul 25, 2017: Lilly Reports Second-Quarter Results 251
Apr 25, 2017: Lilly Reports First-Quarter 2017 Results 255
Jan 31, 2017: Lilly Reports Fourth-Quarter And Full-Year 2016 Results 259
Oct 25, 2016: Lilly Reports Third-Quarter 2016 Results 265
Jul 26, 2016: Lilly Reports Second-Quarter 2016 Results, Provides Financial Expectations Through The Remainder Of The Decade 269
Apr 27, 2016: Acrux: Axiron Net Sales, Quarter To 31 March 2016 273
Apr 26, 2016: Lilly Reports First-Quarter 2016 Results, Revises 2016 Financial Guidance 274
Jan 28, 2016: Lilly Reports Fourth-Quarter And Full-Year 2015 Results 278
Corporate Communications 284
Nov 13, 2017: Lilly Appoints Philip Johnson to Senior Vice President and Treasurer 284
Sep 29, 2017: Lilly Announces Senior Leadership Appointments for Finance, Research & Development and Manufacturing 285
Jun 01, 2017: Derica Rice To Retire As Lilly Chief Financial Officer 286
Feb 09, 2017: Carolyn R. Bertozzi, Ph.D., Elected To Lilly Board Of Directors 287
Oct 12, 2016: Eli Lilly and Company Sponsors Arthritis Foundation ‘Living Your Yes With RA,’ an Initiative to Provide Resources for the Rheumatoid Arthritis Community 288
Aug 31, 2016: Jamere Jackson Elected To Lilly Board Of Directors 289
Jul 27, 2016: John C. Lechleiter to Retire as Lilly CEO; Board Elects David A. Ricks as Successor 290
Jun 13, 2016: Aarti Shah named chief information officer 292
Feb 11, 2016: Lilly Diabetes Helps Inspiring Students With Type 1 Diabetes Attend College Through Scholarship Donation 293
Legal and Regulatory 294
Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 294
Government and Public Interest 295
Apr 04, 2017: Lilly and Ohio University Heritage College of Osteopathic Medicine Partner on Rotation Program for Medical Students 295
Nov 23, 2016: Urgency for Critical Alzheimer’s Disease Treatments Intensifies as Drug Pipeline Receives Setback 296
Oct 11, 2016: Leading Experts Warn Global Goal To Cure Or Treat Alzheimer’s Disease By 2025 Is At Risk, Offer Solutions To Adjust Course 297
Aug 12, 2016: Major grant awarded to new professor to discover how to design new medicines for the treatment of Alzheimer’s Disease 298
Jun 09, 2016: Lilly And American Migraine Foundation Announce $1 Million Grant For Launch Of First Patient Registry To Advance Research And Development In Migraine 300
Mar 01, 2016: US team tackle immune system in £875,000 Dementia Consortium project 301
Feb 24, 2016: Indiana Biosciences Research Institute Announces $100 Million in Grants Supporting Scientific Innovation to Address Metabolic Disease and Poor Nutrition 302
Product News 303
Dec 14, 2017: Companion Medical Announces U.S. Commercial Launch of Smart Insulin Pen System 303
Oct 31, 2016: New Edition Of Online Tool To Measure Cancer Progress To Launch At World Cancer Congress 304
07/18/2016: Cialis now available at a lower price 305
06/22/2016: CoLucid Pharmaceuticals Hosting Key Opinion Leader Meeting in New York City 306
06/12/2017: Drug Candidates Developed Using Zymeworks’ Azymetric Platform Nominated for Late-Stage, Preclinical Development by Lilly 307
05/13/2016: Researchers find blood marker that determines who will respond to colorectal cancer drug 308
03/15/2016: CoLucid Pharmaceuticals Announces Election of Alison Lawton to Board of Directors 309
Jan 19, 2016: Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration 310
Jan 05, 2017: Zymeworks Announces the Successful Achievement of a Research Milestone with Lilly in Bispecific Antibody Collaboration 311
Clinical Trials 312
Aug 31, 2017: Promising One-of-a-kind Clinical Trial Adds Immunotherapy to Colorectal Cancer Treatment Protocol 312
Nov 14, 2016: CoLucid Pharmaceuticals Provides SPARTAN Enrollment Update 313
Oct 05, 2016: CoLucid Pharmaceuticals Announces Additional Analyses of Lasmiditan Onset of Action Data from SAMURAI and Supporting Non-Clinical Data 315
Sep 28, 2016: Merck to Present Data On Erbitux at ESMO 2016 317
Sep 19, 2016: CoLucid Pharmaceuticals Provides Interim Update on GLADIATOR 319
Sep 19, 2016: ERT Takes the Headache out of Migrane Drug Study 321
Sep 17, 2016: CoLucid Pharmaceuticals Announces Achievement of Secondary Endpoints in SAMURAI 322
Sep 06, 2016: CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine 324
Jun 07, 2016: CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine 325
Jun 04, 2016: Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant mCRC Phase III Trial 326
May 19, 2016: CoLucid Pharmaceuticals Announces Initiation of Second Phase 3 Pivotal Trial of Lasmiditan in Migraine 327
May 18, 2016: Lilly to present data on MET antibody emibetuzumab at ASCO 328
May 18, 2016: Lilly to present data on TGFß small-molecule kinase inhibitor galunisertib at ASCO 329
Apr 25, 2016: Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone 330
Mar 01, 2016: CoLucid Pharmaceuticals Announces Special Protocol Agreement for SPARTAN 332
Feb 23, 2016: CoLucid Pharmaceuticals Announces Confirmatory Support for Non-vasoconstrictive Mechanism of Action for Lasmiditan 333
Other Significant Developments 334
Oct 23, 2017: Lilly announces $72 million investment in diabetes manufacturing in Indianapolis 334
Oct 05, 2017: Eli Lilly and Company: Additional Delivery of Insulin Ready for Distribution in Puerto Rico 335
Jul 31, 2017: Boehringer Ingelheim And Lilly To Support New American College Of Cardiology Program To Highlight The Increasingly Important Role Of Cardiologists In Reducing Cardiovascular Risk 336
Jun 21, 2017: Eli Lilly And Company Unveils Expanded Biotechnology Center In San Diego 337
Mar 24, 2017: Lilly Announces $850 Million Investment in U.S. Capital Projects in 2017 338
Jan 05, 2017: Lilly To Adjust Organization And Leadership Structure To Better Align With Growth Opportunities 340
Dec 13, 2016: Lilly Announces Program To Provide Insulin At Discounted Prices 341
Dec 13, 2016: Blink Health Announces Lilly Insulin Patient Access Program 342
Oct 18, 2016: Lilly Announces Ambitious New Commitment To Expand Global Access To Health Care 343
May 24, 2016: Lilly Details Robust R&D Pipeline to Investment Community 345
Jan 05, 2016: Lilly Announces 2016 Financial Guidance, Updates 2015 Expectations 346
Appendix 347
Methodology 347
About GlobalData 347
Contact Us 347
Disclaimer 347

List of Tables
Eli Lilly and Co, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 13
Eli Lilly and Co, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 14
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 15
Eli Lilly and Co, Deals By Therapy Area, 2011 to YTD 2017 16
Eli Lilly and Co, Medical Devices Deals, 2011 to YTD 2017 18
Eli Lilly and Co, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 19
Eli Lilly Acquires Rights to Intranasal Glucagon from Locemia Solutions 33
Eli Lilly Acquires CGRP Antibody From Arteaus Therapeutics 34
Kymera Therapeutics Raises USD30 Million in Series A Venture Financing 35
Gritstone Oncology Raises USD92.7 Million in Series B Financing 36
Hangzhou Just Biotherapeutics Raises USD57 Million in Series B Financing 38
Rodeo Therapeutics Raises USD5.9 Million in Series A Financing 40
E-scape Bio Raises Additional USD8 Million in Series A Financing 42
Abbisko Therapeutics Raises USD28 Million in Series A Financing 43
Cavion Raises USD26 Million in Series A Financing 44
ApoGen Biotech Raises USD7 Million in Series A Financing 45
ReadCoor Raises USD23 Million in Series A Financing 46
Fortis Therapeutics Raises USD18 Million in Series A Financing 47
Singlera Genomics Raises USD20 Million in Series A Financing 48
Just Biotherapeutics Raises USD14 Million in Series A2 Financing 49
IMPACT Therapeutics Raises USD10 Million in Series B Financing 51
Lodo Therapeutics Raises USD17 Million in Series A Financing 52
Zymeworks Raises USD61.5 Million in Series A Financing 54
Petra Pharma Raises USD48 Million in Series A Financing 56
NextCure Raises USD67 Million in Series A Financing 58
Symic Biomedical Raises USD25 Million in Series A-2 Financing 60
ACEA Biosciences Raises USD30 Million in Venture Financing 61
Tianjin CanSino Biotech Raises USD30 Million in Venture Financing Round 62
MabSpace Biosciences Raises USD15 Million in Series A Financing Round 63
Just Biotherapeutics Raises USD15 Million in Series A Financing Round 64
E-scape Bio Raises USD55 Million in Series A Financing 65
Kawin Technology Raises Funds in Venture Financing 66
Protagonist Therapeutics Raises USD40 Million in Series C Financing 67
Innocrin Pharma Raises USD28 Million in Series D Financing 69
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 70
Nimbus Therapeutics Raises USD43 Million in Series B Financing 71
Lysosomal Therapeutics Raises USD20 Million in Series A Financing 72
Surface Oncology Raises USD35 Million in Series A Financing 73
Symic Biomedical Raises USD15 Million in Series A Financing 75
Protagonist Therapeutics Raises Additional Funds through Second Tranche of Series B Venture Financing 76
Aileron Therapeutics Raises USD33 Million in Extended Series E Venture Financing 77
Innocrin Pharma Raises Funds through Venture Financing 79
Viamet Pharma Raises USD60 Million in Series D Venture Financing 80
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 81
IMPACT Therapeutics Raises Funds through Series A Financing 82
Numerate Raises USD8 Million in Financing Round 83
Crown Bioscience Raises USD27 Million in Series D Financing 84
Coherus BioSciences Raises USD55 Million in Series C Venture Financing 85
Lysosomal Therapeutics Raises US$4.8 Million In Seed Financing 87
Audion Therapeutics Raises Funds Through Series A Financing Round 89
Sutro Biopharma Raises US$26 Million In Series D Financing 90
Aileron Therapeutics Raises US$30 Million In Series E Financing 92
Tianjin CanSino Biotech Raises US$10 Million In Venture Financing 94
Aileron Raises US$12 Million In Extended Series D Financing 95
Innovent Biologics Raises US$25 Million In Series B Financing 97
Chinese Peptide Raises Funds Through Series A Financing 98
Sutro Biopharma Raises US$16.5 Million In Second Tranche Of Series C Financing 99
HemaQuest Pharma Raises US$13 Million In Extended Series B Financing 100
Cerulean Pharma Secures US$15 Million In Series D Financing 101
Nimbus Discovery Secures US$24 Million In Series A Financing 103
Viamet Pharma Secures Additional US$15 Million In Series B Financing 104
ImClone Systems Enters Licensing Agreement with Zymeworks 105
Eli Lilly and CureVac Enter into Partnership 106
Topas Therapeutics Enters into Research Agreement with Eli Lilly 107
Eli Lilly and Purdue University Enter into Research Agreement 108
Eli Lilly and KeyBioscience to Enter into Agreement 109
3SBio Enters into Distribution Agreement with Eli Lilly 110
Eli Lilly Enters into Research Agreement with William Sansum Diabetes Center 111
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for MEDI1814 112
Athenex Enters into Partnership with Eli Lilly and Company 113
Eli Lilly Enters into Agreement with Boehringer Ingelheim 114
Regen BioPharma to Enter into Agreement with Eli Lilly 115
AstraZeneca and MedImmune Enter into Agreement with University of Michigan and Eli Lilly 116
Eli Lilly Enters into Agreement with Roche Diagnostics International 117
Eli Lilly Expands its Agreement with Merck 118
WuXi PharmaTech Enters into Agreement with Eli Lilly 119
Yabao Pharma Enters into Co-Development Agreement with Eli Lilly 120
Eli Lilly Enters into Research Agreement with ImaginAb 121
Eli Lilly Japan Partners with Sumitomo Dainippon Pharma 122
Biothera Enters into Research Agreement with Eli Lilly 123
Eli Lilly Enters into Co-Development Agreement with Sarah Cannon Research Institute 124
Eli Lilly Enters into Research Agreement with Dana-Farber Cancer Institute 125
AstraZeneca Expands Research Agreement with Eli Lilly 126
Eli Lilly to Enter into Research Agreement with Sanford Burnham 127
Eli Lilly Enters into Research Agreement with BioNTech 128
Eli Lilly Expands Agreement with Innovent Biologics 129
Merck Expands Agreement with Eli Lilly 130
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 131
Eli Lilly Enters into Agreement with University of Surrey for Diabetes Research 132
Eli Lilly Enters into Research Agreement with Anthem and HealthCore 133
Eli Lilly Amends Co-Promotion Agreement with Boehringer Ingelheim 134
AstraZeneca Enters into Co-Development Agreement with Eli Lilly for AZD3293 136
Eli Lilly Enters into Co-Discover and Development Agreement with Immunocore 137
Yabao Pharma Enters into Co-Development Agreement with Eli Lilly for LY2608204 138
Qiagen Enters into Co-Development Agreement with Eli Lilly for Companion Diagnostic Test 139
Prasco Labs Enters Into Distribution Agreement With Eli Lilly For Evista 140
Cancer Research UK And Eli Lilly Enter Into Agreement To Discover Cancer Treatments 141
Project A.L.S. Enters Into Research Agreement With Eli Lilly 142
Eli Lilly Enters Into Co-Development Agreement With Pfizer For Tanezumab 143
Eli Lilly Enters Into Co-Development Agreement With University of Edinburgh 144
Joslin Diabetes Center Enters Into Co-Development Agreement With Pfizer And Lilly 145
Eli Lilly Enters Into Co-Development Agreement With Novast Labs 146
Zydus Cadila To Terminate Co-Development Agreement With Eli Lilly 147
Arecor Enters Into Co-Development Agreement With Eli Lilly For Protein Therapeutics 148
Starpharma Holdings Expands Research Agreement With Eli Lilly 149
Prasco Labs Enters Into Co-Marketing Agreement With Eli Lilly For ZYPREXA And ZYPREXA ZYDIS 150
Eli Lilly Enters Into Co-Promotion Agreement With Boehringer Ingelheim For Humalog And Linagliptin 151
Eli Lilly and Company (India) Expands its Agreement With Lupin 152
Synthes Enters Into Co-Development Agreement With Eli Lilly 153
Eli Lilly Enters Into Co-Marketing Agreement With Takeda Pharma For Evista 154
Eli Lilly Enters Into Joint Venture Agreement With Care Capital And NovaQuest To Form BioCritica 156
Eli Lilly Enters Into Collaboration With Medtronic 157
Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 158
Receptos Enters Into Collaboration With Eli Lilly 160
Juno Therapeutics Enters into Licensing Agreement with Eli Lilly 161
Eli Lilly to Enter into Licensing Agreement with Nektar Therapeutics 162
Eli Lilly Enters into Licensing Agreement with Adimab 164
Lupin Enters into Licensing Agreement with Eli Lilly and Company 165
Intelgenx Enters into Licensing Agreement with Eli Lilly 166
Cerecor Enters into Licensing Agreement with Eli Lilly 167
Blackthorn Therapeutics Enters into Licensing Agreement with Eli Lilly 168
Eli Lilly Enters into Licensing Agreement with PeptiDream 169
Ignyta Amends Licensing Agreement with Eli Lilly 170
Zhejiang Hisun Pharma Enters into Licensing Agreement with Eli Lilly for Capreomycin 172
Eli Lilly to Enter into Licensing Agreement with Hanmi Pharma 173
Cerecor Enters into Licensing Agreement with Eli Lilly 174
Amunix Exercises Option for Licensing Agreement with Eli Lilly 176
Eli Lilly Enters into Licensing Agreement with Zymeworks 177
Anthera Pharma Enters into Licensing Agreement with Eli Lilly for Sollpura 178
Sanofi Enters into Licensing Agreement with Eli Lilly for Cialis 179
PeptiDream Enters Into Licensing Agreement With Eli Lilly 180
Hutchison MediTech Enters Into Licensing Agreement With Eli Lilly 181
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 183
Deciphera Pharma Extends Its Licensing Agreement With Eli Lilly and Company 184
Dekkun Enters into Licensing Agreement with Eli Lilly and Company 185
IntelGenx Enters into Licensing Agreement with Eli Lilly and Company 186
Halozyme Therapeutics Enters into Licensing Agreement with Eli Lilly and Company 187
Transition Therapeutics Enters into Licensing Agreement with Eli Lilly for TT701 188
Denovo Biopharma Enters into Licensing Agreement with Eli Lilly for Pomaglumetad Methionil 189
Audion Therapeutics Enters Into Licensing Agreement With Eli Lilly and Company 190
ImmunoGen Extends Licensing Agreement With Eli Lilly For Targeted Antibody Payload Technology 191
Transition Therapeutics Enters Into Licensing Agreement With Eli Lilly For TT-601 192
Transition Therapeutics and Eli Lilly Amend Licensing Agreement 193
Strides Arcolab Enters Into Licensing Agreement With Eli Lilly For Generic Cancer Medicines 195
R-Pharm Enters into Licensing Agreement with Eli Lilly 196
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 197
Bend Research Enters Into Licensing Agreement With Eli Lilly For SDD Technology 199
Ligand Pharma Enters Into Licensing Agreement With Eli Lilly 200
ImmunoGen Enters Into Licensing Agreement With Eli Lilly 201
Adocia Enters Into Licensing Agreement With Eli Lilly For BioChaperone 202
arGEN-X Enters Into Licensing Agreement With Eli Lilly 203
Leap Therapeutics to Raise USD18 Million in Private Placement of Units 204
Tmunity Therapeutics Raises USD10 Million in Equity Financing 206
Ignyta Raises USD30 Million in Private Placement of Shares 207
Immunocore Raises USD320 Million in Financing Round 208
Eli Lilly Raises USD201 Million in Public Offering of Notes Due 2018 209
Eli Lilly Raises USD603.7 Million in Public Offering of 0.15% Notes Due 2024 210
Eli Lilly Raises USD402.5 Million in Public Offering of 0.45% Notes Due 2028 211
Eli Lilly Prices Public Offering of 2.1% Bonds Due 2030 for USD823.6 Million 212
Eli Lilly Prices Public Offering of 1.6% Bonds Due 2026 for USD823.6 Million 213
Eli Lilly Prices Public Offering of 1% Bonds Due 2022 for USD659 Million 214
Eli Lilly Raises USD800 Million in Public Offering of 2.75% Notes Due 2025 215
Eli Lilly Raises USD800 Million in Public Offering of 3.7% Notes Due 2045 216
Eli Lilly Raises USD600 Million in Public Offering of 1.25% Notes Due 2018 217
Eli Lilly Raises USD400 Million in Public Offering of 4.65% Notes Due 2044 218
Eli Lilly Raises USD600 Million in Public Offering of 1.95% Notes Due 2019 219
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 220
Eli Lilly to Sell Bio-manufacturing Plant in Vacaville, California 221
Virbac Acquires Sentinel Flavor Tabs and Sentinel Spectrum from Eli Lilly for USD410 Million 222
Denovo Biopharma Acquires Global Rights to Enzastaurin from Eli Lilly 223
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 224
Trimer Biotech Acquires AME-527 from Eli Lilly 225
MENTRIK Biotech Acquires Rights Of AME-133v From Eli Lilly 226
Eli Lilly Acquires CoLucid Pharma for USD960 Million in Tender Offer 227
Eli Lilly and Company Acquires Glycostasis 229
AstraZeneca May Acquire Ariad Pharma 230
Eli Lilly and Co, Key Competitors 232
Eli Lilly and Co, Key Employees 233
Eli Lilly and Co, Subsidiaries 235
Eli Lilly and Co, Joint Venture 242

★海外企業調査レポート[Eli Lilly and Co (LLY)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Tessi S.A. (TES)：企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Y.S.P. Southeast Asia Holding Berhad (YSPSAH)：企業の財務・戦略的SWOT分析
    Y.S.P. Southeast Asia Holding Berhad (YSPSAH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • University of Michigan-製薬・医療分野：企業M&A・提携分析
    Summary University of Michigan (UM) is an educational service provider that offers educational and research services. The university offers graduate, undergraduate and post-doctoral levels programs in various disciplines. It operates various graduate schools and colleges of graduate studies, archite …
  • Cryosite Ltd (CTE)：企業の財務・戦略的SWOT分析
    Summary Cryosite Ltd (Cryosite) is a healthcare solution provider that offers clinical trials outsourced logistics services to research, medical, pharmaceutical, veterinary and biotechnology industries. The company manufactures stem cell products for both therapeutic use and clinical trials. It prov …
  • Pilot Energy Ltd (PGY)：企業の財務・戦略的SWOT分析
    Summary Pilot Energy Ltd (Pilot), formerly known as Rampart Energy Ltd, is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in Australia. Its projects include Australia EP416 and EP480, Australia WA-481-P, and Australia EP …
  • Merz Pharma GmbH & Co KgaA：医療機器：M&Aディール及び事業提携情報
    Summary Merz Pharma GmbH & Co KgaA (Merz Pharma) is an aesthetics and neurotoxin company that develops products for aesthetic and medical dermatology and neurological movement disorders. The company’s products include aesthetics, ethical drugs, over-the-counter drugs, neurology, and central nervous …
  • Statewide Superannuation Pty Ltd：企業の戦略的SWOT分析
    Statewide Superannuation Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Omnicell Inc (OMCL)：医療機器：M&Aディール及び事業提携情報
    Summary Omnicell Inc (Omnicell) is a provider of automation and business analytics software solutions. It provides medication control and patient safety solutions to enhance operational efficiency and patient care in acute healthcare facilities. The company offers automation solutions such as medica …
  • Smithfield Foods Inc：戦略・SWOT・企業財務分析
    Smithfield Foods Inc - Strategy, SWOT and Corporate Finance Report Summary Smithfield Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Blue Apron Holdings Inc (APRN)：企業の財務・戦略的SWOT分析
    Blue Apron Holdings Inc (APRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • First Solar, Inc.：企業の戦略・SWOT・財務情報
    First Solar, Inc. - Strategy, SWOT and Corporate Finance Report Summary First Solar, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sotheby’s (BID)：企業の財務・戦略的SWOT分析
    Sotheby's (BID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Ixia (XXIA)：企業の財務・戦略的SWOT分析
    Summary Ixia (Ixia), a subsidiary of Keysight Technologies Inc, is a technology company that offers test architecture solutions and services. The company's products potfolio include visibility, test, cloud, security, performance monitoring, and test hardware products. Its security products comprise …
  • Celulose Nipo-Brasileira SA：企業の戦略的SWOT分析
    Celulose Nipo-Brasileira SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • Valeo SA (FR)：企業の財務・戦略的SWOT分析
    Valeo SA (FR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • MSL Solutions Limited (MPW)：企業の財務・戦略的SWOT分析
    MSL Solutions Limited (MPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • i-Optics BV-医療機器分野：企業M&A・提携分析
    Summary i-Optics BV (i-Optics) is a medical device company that manufactures and distributes optical devices. The company provides easyscan, eyeprevent and cassini for age related eye diseases. The company’s cassini is a corneal topography measurement device for contact lens fitting, corneal transpl …
  • Ambac Financial Group Inc (AMBC)：企業の財務・戦略的SWOT分析
    Ambac Financial Group Inc (AMBC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Gasum Oy：石油・ガス：M&Aディール及び事業提携情報
    Summary Gasum Oy (Gasum), a subsidiary of Gasonia Oy is an oil and gas company that offers natural gas trading services. The company provides biogas and natural gas for use as a transport fuel, energy production, liquefied natural gas, shipping fuel, and natural gas for electricity and district heat …
  • Kepler Weber S.A. (KEPL3)：企業の財務・戦略的SWOT分析
    Kepler Weber S.A. (KEPL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆